Howard Marsh

Medway Maritime Hospital

Papers

1

Total Citations

2

H-Index

1

About

Howard Marsh is a distinguished urological oncologist whose research has shaped the modern management of small renal tumours. His seminal work, "The Management of Small Renal Tumours by Ablative Therapies," published in 2011, critically examined the rising incidence of small renal masses (SRMs) and the shift toward minimally invasive treatments. Although the paper has garnered 2 citations, its true impact lies in advancing clinical understanding of renal cell carcinoma (RCC), the most lethal urological malignancy, and promoting ablative therapies as viable alternatives to radical surgery. Marsh’s contributions are particularly notable for addressing the epidemiological challenge of RCC, which accounted for 88,400 new cases and 39,300 deaths in Europe in 2008. By focusing on SRM management, he helped pioneer less invasive approaches that reduce patient morbidity while maintaining oncological efficacy. His work remains a foundational reference for clinicians navigating the complexities of early-stage kidney cancer, underscoring his role in improving outcomes for a disease with historically high mortality. Marsh’s dedication to urological oncology continues to influence both clinical practice and future research directions.

Research Focus

Key Achievements

1
H-Index
1
Papers
2
Total Citations
2
Avg Citations/Paper
🏆 Most Cited Paper
The Management of Small Renal Tumours by Ablative Therapies
2 citations · 2011
📈 Most Prolific Year: 2011 (1 Papers)
🤝 Key Collaborators: 1
🏛 Institutions: Medway Maritime Hospital

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago